J&J Tried To Obscure Risperdal Risks, Ex-FDA Chief Says
Ex-U.S. Food and Drug Administration Commissioner David Kessler testified Thursday that a Johnson & Johnson subsidiary had worked to obscure a significant association between the blockbuster antipsychotic drug Risperdal with incidences...To view the full article, register now.
Already a subscriber? Click here to view full article